1. Home
  2. ENVB

as of 12-09-2025 11:55am EST

$6.18
+$0.11
+1.80%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Chart Type:
Time Range:
Founded: 1994 Country:
United States
United States
Employees: N/A City: NAPLES
Market Cap: 3.0M IPO Year: N/A
Target Price: $120.00 AVG Volume (30 days): 33.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -61.29 EPS Growth: N/A
52 Week Low/High: $4.88 - $96.30 Next Earning Date: 11-14-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered ENVB Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 18 hours ago

AI Recommendation

hold
Model Accuracy: 73.47%
73.47%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Enveric Biosciences Inc. News

ENVB Breaking Stock News: Dive into ENVB Ticker-Specific Updates for Smart Investing

All ENVB News

Share on Social Networks: